Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study

OBJECTIVES: Bimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Bourne, Rupert Richard Alexander, Kaarniranta, Kai, Lorenz, Katrin, Traverso, Carlo Enrico, Vuorinen, Jouni, Ropo, Auli
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6500185/
https://ncbi.nlm.nih.gov/pubmed/30944129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-024129
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados